GlobeNewsWire
06 Jan 2026, 14:30 UTC · 44w ago
Impact · against what's priced in
Coherus Oncology is showing positive commercial momentum for LOQTORZI and promising early clinical activity for tagmokitug. These updates, alongside the upcoming J.P. Morgan conference presentation, provide a net positive catalyst for the stock's valuation.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish
Coherus Oncology reported LOQTORZI net revenue of $13.6 million in Q2 2026, representing a 15% increase over Q1.
More positive than 76% of claims this week
Clinical data for tagmokitug is maturing with emerging evidence of activity in head and neck cancer.
Continue reading
5 related stories
Sequential revenue growth for LOQTORZI ($13.6 million in Q2 2026, up 15% over Q1) and emerging activity data for tagmokitug in head and neck cancer suggest improving commercial and clinical viability.
Read from the article alone
Scored by the NIS engine · methodology.
Search tags
More positive than 63% of claims this week
Coherus management will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026.
More positive than 42% of claims this week
Which stocks this story touches
More positive than 63% of ticker scores this week
The company is presenting at a major healthcare conference and reporting revenue growth for its drug LOQTORZI.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
15h ago
—
No price for CHRS right now — the quote feed didn't answer.
CHRS chart →
